{"success":true,"data":{"pressRelease":{"id":"149420","rtpr_id":"nGNX2scNtv-20260922","ticker":"WVE","exchange":"NASDAQ","all_tickers":["WVE"],"title":"Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer","author":"Globe Newswire","published_at":"2026-09-22T11:30:00.264Z","article_body":"Dr. Vnuk brings substantial business and corporate development leadership\nexperience from Sanofi, Blackstone, and Pfizer\n\nCAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.\n(Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the\nbroad potential of RNA medicines to transform human health, today announced\nthe appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will\njoin Wave’s executive team and lead business development, corporate\ndevelopment, and alliance management.\n\n“We are thrilled to welcome Dr. Vnuk to Wave in a newly created leadership\nrole as we continue to advance our pipeline to the next stages of development.\nMonika’s breadth of experience, including leading global business\ndevelopment teams and strategic asset financing, will be meaningful as we\ncontinue to expand the potential of our differentiated RNA medicines platform\nand support the next phase of Wave’s growth,” said Paul Bolno, MD, MBA,\nPresident and Chief Executive Officer of Wave Life Sciences.\n\n“Wave has built a highly versatile and differentiated RNA medicines platform\nwith multiple therapeutic modalities translating in the clinic. I am energized\nto join the company at such an exciting moment, as its science and pipeline\nprograms create broad opportunity to advance value-creating transactions with\nthe ultimate aim of expanding Wave’s positive impact on patients. I look\nforward to partnering with the Wave team to help drive the company’s growth\nand realize the full potential of its platform and pipeline,” said Monika\nVnuk, MD, Chief Business Officer of Wave Life Sciences.\n\nPrior to joining Wave, Dr. Vnuk served as Senior Vice President, Global Head\nof Partnering and Business Development for Sanofi, where she led global\nlicensing, equity investments, and alliances. Prior to Sanofi, she was\nManaging Director at Blackstone Life Sciences, a private life sciences\ninvesting platform, where she was focused on late-stage product financing\ntransactions. Dr. Vnuk spent more than a decade at Pfizer in senior business\ndevelopment roles, including Vice President, R&D Business Development, where\nshe led the negotiation of the successful partnership with BioNTech directed\nat the global co-development and distribution of COVID-19 vaccines. Before\nPfizer, she worked in investment banking at Bank of America and the life\nsciences venture capital firm Oxford Bioscience Partners. Dr. Vnuk earned an\nM.D. from Boston University School of Medicine and a B.A. in Mathematics and\nPhilosophy from Boston University.\n\nIn connection with Dr. Vnuk joining Wave, she received a stock option to\npurchase 375,000 shares of common stock of Wave. The equity grant was approved\nby Wave’s Compensation Committee and granted to Dr. Vnuk on September 21,\n2026, outside of the Wave Life Sciences, Inc. Amended and Restated 2021\nEquity Incentive Plan, as an inducement material to Dr. Vnuk’s commencing\nemployment with Wave, in accordance with Nasdaq Stock Market Listing Rule\n5635(c)(4). The option has an exercise price of $4.25 per share, the closing\nprice on the grant date, and vests over four years with 25% vesting\non September 21, 2027, and the remainder vesting in equal quarterly\ninstallments over the following three years.\n\nAbout Wave Life Sciences\nWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on\nunlocking the broad potential of RNA medicines to transform human health.\nWave’s RNA medicines platform, PRISM®, combines multiple modalities,\nchemistry innovation, and deep insights in human genetics to deliver\nscientific breakthroughs that treat both rare and common disorders. Its\ntoolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing\n(AIMers), provides Wave with unmatched capabilities for designing and\nsustainably delivering candidates that optimally address disease biology.\nWave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin\ndeficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and\nalso includes clinical programs in Duchenne muscular dystrophy and\nHuntington’s disease, as well as several preclinical programs utilizing the\ncompany’s versatile RNA medicines platform. Driven by the calling to\n“Reimagine Possible,” Wave is leading the charge toward a world in which\nhuman potential is no longer hindered by the burden of disease. Wave is\nheadquartered in Cambridge, MA. For more information on Wave’s science,\npipeline and people, please visit www.wavelifesciences.com and follow Wave on\nX\n(https://www.globenewswire.com/Tracker?data=soaqS7IN0Gf4IZwBj0ZMNHbvWLShYrml6BwShWRzVo0CgNE0s0t-9U9oPwzPed9uP1y66AMwp6mmkk2ltEY1zQ==)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=636Caw4KXCjqHPHFZ6jBTRmmCztp9rg5d0_-Ehb6Kbfh9RjWpyWaWUse8rK16yAzjUyRRjFKxf1fw1m8b4SZ4U3ZfBWZLEKx67FCP_TRGUTkbrfEHhjNSIR6Tj4yZSP-).\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, as amended, including,\nwithout limitation, statements regarding Dr. Vnuk’s leadership and global\nexperience leading business development teams and strategic asset financing,\nstrategic partnerships, licensing, equity investments and alliances; beliefs\nthat Dr. Vnuk’s experience will benefit the next phase of Wave’s growth;\nbeliefs that Wave’s portfolio of RNA medicines is differentiated,\nbest-in-class and potentially transformative; the broad potential of Wave’s\nRNA medicines pipeline and oligonucleotide chemistry and any benefits that may\nbe derived from them. The words “may,” “will,” “could,”\n“would,” “should,” “expect,” “plan,” “anticipate,”\n“intend,” “believe,” “estimate,” “predict,” “project,”\n“potential,” “continue,” “target” and similar expressions are\nintended to identify forward-looking statements, although not all\nforward-looking statements contain these identifying words. Any\nforward-looking statements in this press release are based on management’s\ncurrent expectations and beliefs and are subject to a number of risks,\nuncertainties and important factors that may cause actual events or results to\ndiffer materially from those expressed or implied by any forward-looking\nstatements contained in this press release and actual results may differ\nmaterially from those indicated by these forward-looking statements as a\nresult of these risks, uncertainties and important factors, including, without\nlimitation, the risks and uncertainties described in the section entitled\n“Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed\nwith the Securities and Exchange Commission (SEC), as amended, and in other\nfilings Wave makes with the SEC from time to time. Wave undertakes no\nobligation to update the information contained in this press release to\nreflect subsequently occurring events or circumstances.\n\nContact:\nKate Rausch\nVP, Corporate Affairs and Investor Relations\n+1 617-949-4827\n\nInvestors:\nJames Salierno\nDirector, Investor Relations\n+1 617-949-4043 \nInvestorRelations@wavelifesci.com\n\nMedia:\nKatie Sullivan\nSenior Director, Corporate Communications\n+1 617-949-2936\nMediaRelations@wavelifesci.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b2c5e218-8ae8-4dc2-b6f2-cf55b6b3b6e0)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2scNtv-20260922","title":"Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer","author":"Globe Newswire","ticker":"WVE","created":"2026-09-22T11:30:00.264Z","tickers":["WVE"],"exchange":"NASDAQ","article_body":"Dr. Vnuk brings substantial business and corporate development leadership\nexperience from Sanofi, Blackstone, and Pfizer\n\nCAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.\n(Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the\nbroad potential of RNA medicines to transform human health, today announced\nthe appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will\njoin Wave’s executive team and lead business development, corporate\ndevelopment, and alliance management.\n\n“We are thrilled to welcome Dr. Vnuk to Wave in a newly created leadership\nrole as we continue to advance our pipeline to the next stages of development.\nMonika’s breadth of experience, including leading global business\ndevelopment teams and strategic asset financing, will be meaningful as we\ncontinue to expand the potential of our differentiated RNA medicines platform\nand support the next phase of Wave’s growth,” said Paul Bolno, MD, MBA,\nPresident and Chief Executive Officer of Wave Life Sciences.\n\n“Wave has built a highly versatile and differentiated RNA medicines platform\nwith multiple therapeutic modalities translating in the clinic. I am energized\nto join the company at such an exciting moment, as its science and pipeline\nprograms create broad opportunity to advance value-creating transactions with\nthe ultimate aim of expanding Wave’s positive impact on patients. I look\nforward to partnering with the Wave team to help drive the company’s growth\nand realize the full potential of its platform and pipeline,” said Monika\nVnuk, MD, Chief Business Officer of Wave Life Sciences.\n\nPrior to joining Wave, Dr. Vnuk served as Senior Vice President, Global Head\nof Partnering and Business Development for Sanofi, where she led global\nlicensing, equity investments, and alliances. Prior to Sanofi, she was\nManaging Director at Blackstone Life Sciences, a private life sciences\ninvesting platform, where she was focused on late-stage product financing\ntransactions. Dr. Vnuk spent more than a decade at Pfizer in senior business\ndevelopment roles, including Vice President, R&D Business Development, where\nshe led the negotiation of the successful partnership with BioNTech directed\nat the global co-development and distribution of COVID-19 vaccines. Before\nPfizer, she worked in investment banking at Bank of America and the life\nsciences venture capital firm Oxford Bioscience Partners. Dr. Vnuk earned an\nM.D. from Boston University School of Medicine and a B.A. in Mathematics and\nPhilosophy from Boston University.\n\nIn connection with Dr. Vnuk joining Wave, she received a stock option to\npurchase 375,000 shares of common stock of Wave. The equity grant was approved\nby Wave’s Compensation Committee and granted to Dr. Vnuk on September 21,\n2026, outside of the Wave Life Sciences, Inc. Amended and Restated 2021\nEquity Incentive Plan, as an inducement material to Dr. Vnuk’s commencing\nemployment with Wave, in accordance with Nasdaq Stock Market Listing Rule\n5635(c)(4). The option has an exercise price of $4.25 per share, the closing\nprice on the grant date, and vests over four years with 25% vesting\non September 21, 2027, and the remainder vesting in equal quarterly\ninstallments over the following three years.\n\nAbout Wave Life Sciences\nWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on\nunlocking the broad potential of RNA medicines to transform human health.\nWave’s RNA medicines platform, PRISM®, combines multiple modalities,\nchemistry innovation, and deep insights in human genetics to deliver\nscientific breakthroughs that treat both rare and common disorders. Its\ntoolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing\n(AIMers), provides Wave with unmatched capabilities for designing and\nsustainably delivering candidates that optimally address disease biology.\nWave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin\ndeficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and\nalso includes clinical programs in Duchenne muscular dystrophy and\nHuntington’s disease, as well as several preclinical programs utilizing the\ncompany’s versatile RNA medicines platform. Driven by the calling to\n“Reimagine Possible,” Wave is leading the charge toward a world in which\nhuman potential is no longer hindered by the burden of disease. Wave is\nheadquartered in Cambridge, MA. For more information on Wave’s science,\npipeline and people, please visit www.wavelifesciences.com and follow Wave on\nX\n(https://www.globenewswire.com/Tracker?data=soaqS7IN0Gf4IZwBj0ZMNHbvWLShYrml6BwShWRzVo0CgNE0s0t-9U9oPwzPed9uP1y66AMwp6mmkk2ltEY1zQ==)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=636Caw4KXCjqHPHFZ6jBTRmmCztp9rg5d0_-Ehb6Kbfh9RjWpyWaWUse8rK16yAzjUyRRjFKxf1fw1m8b4SZ4U3ZfBWZLEKx67FCP_TRGUTkbrfEHhjNSIR6Tj4yZSP-).\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, as amended, including,\nwithout limitation, statements regarding Dr. Vnuk’s leadership and global\nexperience leading business development teams and strategic asset financing,\nstrategic partnerships, licensing, equity investments and alliances; beliefs\nthat Dr. Vnuk’s experience will benefit the next phase of Wave’s growth;\nbeliefs that Wave’s portfolio of RNA medicines is differentiated,\nbest-in-class and potentially transformative; the broad potential of Wave’s\nRNA medicines pipeline and oligonucleotide chemistry and any benefits that may\nbe derived from them. The words “may,” “will,” “could,”\n“would,” “should,” “expect,” “plan,” “anticipate,”\n“intend,” “believe,” “estimate,” “predict,” “project,”\n“potential,” “continue,” “target” and similar expressions are\nintended to identify forward-looking statements, although not all\nforward-looking statements contain these identifying words. Any\nforward-looking statements in this press release are based on management’s\ncurrent expectations and beliefs and are subject to a number of risks,\nuncertainties and important factors that may cause actual events or results to\ndiffer materially from those expressed or implied by any forward-looking\nstatements contained in this press release and actual results may differ\nmaterially from those indicated by these forward-looking statements as a\nresult of these risks, uncertainties and important factors, including, without\nlimitation, the risks and uncertainties described in the section entitled\n“Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed\nwith the Securities and Exchange Commission (SEC), as amended, and in other\nfilings Wave makes with the SEC from time to time. Wave undertakes no\nobligation to update the information contained in this press release to\nreflect subsequently occurring events or circumstances.\n\nContact:\nKate Rausch\nVP, Corporate Affairs and Investor Relations\n+1 617-949-4827\n\nInvestors:\nJames Salierno\nDirector, Investor Relations\n+1 617-949-4043 \nInvestorRelations@wavelifesci.com\n\nMedia:\nKatie Sullivan\nSenior Director, Corporate Communications\n+1 617-949-2936\nMediaRelations@wavelifesci.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b2c5e218-8ae8-4dc2-b6f2-cf55b6b3b6e0)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-22T11:30:00.302225253Z","server_sent_at_ms":1790076600302},"received_at":"2026-09-22T11:30:00.423Z","source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366177/0/en/wave-life-sciences-announces-appointment-of-dr-monika-vnuk-as-chief-business-officer.html"},"analysis":{"id":"138266","press_release_id":"149420","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Wave Life Sciences appointed Dr. Monika Vnuk as Chief Business Officer, a newly created role leading business development, corporate development, and alliance management.\n\nDr. Vnuk joins from Sanofi, where she was Senior Vice President and Global Head of Partnering and Business Development; she previously spent more than a decade at Pfizer — including leading negotiation of the Pfizer-BioNTech COVID-19 vaccine partnership — and served as Managing Director at Blackstone Life Sciences.\n\nIn connection with her appointment, she received an inducement stock option for 375,000 shares at a $4.25 exercise price, granted outside the 2021 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4) and vesting over four years with 25% vesting on September 21, 2027.\n\nThe hire signals Wave's intent to pursue value-creating transactions as its clinical pipeline — led by obesity candidate WVE-007 and AATD program WVE-006 — advances toward later stages.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Clinical-stage RNA medicines play hires a Pfizer-BioNTech deal architect as its first Chief Business Officer — a setup worth watching for partnership or licensing speculation."},"keyFigures":{"customDimensions":{"first_vesting_pct":"25%","option_grant_date":"2026-09-21","option_vesting_years":4,"inducement_option_shares":375000,"option_exercise_price_usd":4.25}},"quotedText":"We are thrilled to welcome Dr. Vnuk to Wave in a newly created leadership role as we continue to advance our pipeline to the next stages of development","namedEntities":{"people":[{"name":"Dr. Monika Vnuk","role":"Chief Business Officer (newly appointed), Wave Life Sciences"},{"name":"Paul Bolno","role":"President and Chief Executive Officer, Wave Life Sciences"}],"products":["PRISM RNA medicines platform","WVE-007 (obesity)","WVE-006 (alpha-1 antitrypsin deficiency)","WVE-008 (PNPLA3 I148M liver disease)"],"companies":[{"name":"Wave Life Sciences Ltd.","ticker":"WVE","relationship":"filer"},{"name":"Sanofi","relationship":"prior employer (SVP, Global Head of Partnering and Business Development)"},{"name":"Blackstone Life Sciences","relationship":"prior employer (Managing Director)"},{"name":"Pfizer","relationship":"prior employer (10+ years in business development)"},{"name":"BioNTech","relationship":"counterparty of Pfizer COVID-19 vaccine partnership Dr. Vnuk negotiated"},{"name":"Bank of America","relationship":"prior employer (investment banking)"},{"name":"Oxford Bioscience Partners","relationship":"prior employer (life sciences venture capital)"}],"dollarAmounts":[{"amount":"$4.25","context":"per-share exercise price of the inducement stock option (grant-date closing price)"}]},"materialImpact":{"score":2,"reasoning":"Non-CEO C-suite appointment at a clinical-stage biotech — routine on its own, but the hire is a newly created Chief Business Officer role filled by an executive with heavyweight deal credentials (led Pfizer's BioNTech COVID-19 vaccine partnership negotiation), hinting at future partnership or licensing activity. The accompanying inducement option grant (~375,000 shares) is standard practice."},"tickerRelevance":{"others":[],"primary":"WVE"},"globalImportance":12,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"non-CEO executive appointment","issuerAuthored":true,"dealPedigreeSignal":"new CBO's BioNTech deal history may fuel BD speculation but is not itself a market event","householdBrandBoost":false,"retailFavoriteBoost":"moderate — WVE has retail follow-through on RNA editing and obesity programs"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Wave Life Sciences appointed Dr. Monika Vnuk as Chief Business Officer, a newly created role leading business development, corporate development, and alliance management.\n\nDr. Vnuk joins from Sanofi, where she was Senior Vice President and Global Head of Partnering and Business Development; she previously spent more than a decade at Pfizer — including leading negotiation of the Pfizer-BioNTech COVID-19 vaccine partnership — and served as Managing Director at Blackstone Life Sciences.\n\nIn connection with her appointment, she received an inducement stock option for 375,000 shares at a $4.25 exercise price, granted outside the 2021 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4) and vesting over four years with 25% vesting on September 21, 2027.\n\nThe hire signals Wave's intent to pursue value-creating transactions as its clinical pipeline — led by obesity candidate WVE-007 and AATD program WVE-006 — advances toward later stages.","key_figures":{"customDimensions":{"first_vesting_pct":"25%","option_grant_date":"2026-09-21","option_vesting_years":4,"inducement_option_shares":375000,"option_exercise_price_usd":4.25}},"named_entities":{"people":[{"name":"Dr. Monika Vnuk","role":"Chief Business Officer (newly appointed), Wave Life Sciences"},{"name":"Paul Bolno","role":"President and Chief Executive Officer, Wave Life Sciences"}],"products":["PRISM RNA medicines platform","WVE-007 (obesity)","WVE-006 (alpha-1 antitrypsin deficiency)","WVE-008 (PNPLA3 I148M liver disease)"],"companies":[{"name":"Wave Life Sciences Ltd.","ticker":"WVE","relationship":"filer"},{"name":"Sanofi","relationship":"prior employer (SVP, Global Head of Partnering and Business Development)"},{"name":"Blackstone Life Sciences","relationship":"prior employer (Managing Director)"},{"name":"Pfizer","relationship":"prior employer (10+ years in business development)"},{"name":"BioNTech","relationship":"counterparty of Pfizer COVID-19 vaccine partnership Dr. Vnuk negotiated"},{"name":"Bank of America","relationship":"prior employer (investment banking)"},{"name":"Oxford Bioscience Partners","relationship":"prior employer (life sciences venture capital)"}],"dollarAmounts":[{"amount":"$4.25","context":"per-share exercise price of the inducement stock option (grant-date closing price)"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-22T15:58:02.492Z","global_importance":12,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"non-CEO executive appointment","issuerAuthored":true,"dealPedigreeSignal":"new CBO's BioNTech deal history may fuel BD speculation but is not itself a market event","householdBrandBoost":false,"retailFavoriteBoost":"moderate — WVE has retail follow-through on RNA editing and obesity programs"}},"durationMs":150025,"modelName":"glm-5.3-flash"}}